Treatment of Relapsed or Refractory Neuroblastoma With Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2

Trial Profile

Treatment of Relapsed or Refractory Neuroblastoma With Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary) ; Natural killer cell therapy
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.
    • 06 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
    • 14 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top